Literature DB >> 15805244

Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice.

Xiaoyang Ling1, Ralph B Arlinghaus.   

Abstract

Constitutively activated STAT3 is involved in the formation of multiple types of tumors including breast cancer. We examined the effects of Stat3 protein knockdown by RNA interference using a dicistronic lentivirus small hairpin (shRNA) delivery system on the growth of mammary tumors in BALB/c mice induced by the 4T1 cell line. A single exposure of 4T1 cells to shRNA/STAT3 lentivirus transduced 75% of the cells with green fluorescent protein (GFP) within 96 hours. In cells selected for GFP expression, neither Stat3 protein nor phosphotyrosine Stat3 was detected. Tumor formation induced by injecting 4T1 cells into the mammary fat pad was blocked by expression of the shRNA for STAT3 whereas all mice injected with 4T1 cells expressing only GFP efficiently formed tumors. c-Myc expression was reduced 75% in cells expressing greatly reduced levels of Stat3 compared with the GFP control. Of interest, the level of activated Src, which is known to activate Stat3, was virtually eliminated but the level of the Src protein itself remained the same. Importantly, expression of Twist protein, a metastatic regulator, was eliminated in STAT3 knockdown cells. Invasion activity of STAT3 knockdown cells was strongly inhibited. However, the proliferation rate of cells in Stat3 knockdown cells was similar to that of the GFP control; the cell cycle was also not affected. We conclude from these studies that activated Stat3 protein plays a critical role in the induction of breast tumors induced by 4T1 cells by enhancing the expression of several important genes including c-Myc and the metastatic regulator Twist. These studies suggest that stable expression of small interfering RNA for STAT3 has potential as a therapeutic strategy for breast cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15805244     DOI: 10.1158/0008-5472.CAN-04-2425

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  81 in total

1.  Signal transducers and activators of transcription 3 (STAT3) directly regulates cytokine-induced fascin expression and is required for breast cancer cell migration.

Authors:  Marylynn Snyder; Xin-Yun Huang; J Jillian Zhang
Journal:  J Biol Chem       Date:  2011-09-20       Impact factor: 5.157

2.  Withaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells.

Authors:  Joomin Lee; Eun-Ryeong Hahm; Shivendra V Singh
Journal:  Carcinogenesis       Date:  2010-08-19       Impact factor: 4.944

3.  Persistent GP130/STAT3 Signaling Contributes to the Resistance of Doxorubicin, Cisplatin, and MEK Inhibitor in Human Rhabdomyosarcoma Cells.

Authors:  Xiaojuan Wu; Hui Xiao; Ruoning Wang; Lingling Liu; Chenglong Li; Jiayuh Lin
Journal:  Curr Cancer Drug Targets       Date:  2016       Impact factor: 3.428

4.  Antitumorigenic potential of STAT3 alternative splicing modulation.

Authors:  Francesca Zammarchi; Elisa de Stanchina; Eirini Bournazou; Teerawit Supakorndej; Kathryn Martires; Elyn Riedel; Adriana D Corben; Jacqueline F Bromberg; Luca Cartegni
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-17       Impact factor: 11.205

Review 5.  The biological functions of the versatile transcription factors STAT3 and STAT5 and new strategies for their targeted inhibition.

Authors:  Sylvane Desrivières; Christian Kunz; Itamar Barash; Vida Vafaizadeh; Corina Borghouts; Bernd Groner
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-01       Impact factor: 2.673

Review 6.  Targeting STAT3 in cancer: how successful are we?

Authors:  Peibin Yue; James Turkson
Journal:  Expert Opin Investig Drugs       Date:  2009-01       Impact factor: 6.206

7.  Caveolin-1 upregulation mediates suppression of primary breast tumor growth and brain metastases by stat3 inhibition.

Authors:  Wen-Tai Chiu; Hsueh-Te Lee; Feng-Ju Huang; Kenneth D Aldape; Jun Yao; Patricia S Steeg; Cheng-Yang Chou; Zhimin Lu; Keping Xie; Suyun Huang
Journal:  Cancer Res       Date:  2011-05-27       Impact factor: 12.701

8.  Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA.

Authors:  Yuelong Ma; Claudia M Kowolik; Piotr M Swiderski; Marcin Kortylewski; Hua Yu; David A Horne; Richard Jove; Otavia L Caballero; Andrew J G Simpson; Fook-Thean Lee; Vinochani Pillay; Andrew M Scott
Journal:  ACS Chem Biol       Date:  2011-07-26       Impact factor: 5.100

Review 9.  STAT3 regulation of glioblastoma pathogenesis.

Authors:  Núria de la Iglesia; Sidharth V Puram; Azad Bonni
Journal:  Curr Mol Med       Date:  2009-06       Impact factor: 2.222

10.  Increased levels of active c-Src distinguish invasive from in situ lobular lesions.

Authors:  Donghui Zou; Han-Seung Yoon; Ahmad Anjomshoaa; David Perez; Ryuji Fukuzawa; Parry Guilford; Bostjan Humar
Journal:  Breast Cancer Res       Date:  2009-07-07       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.